Augmented Hybrid NIRF-IVUS: A Groundbreaking Technology for Molecular Imaging of Coronary Artery Disease
Presenter:
We Recommend
Disclosures
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
- Grant Support/Research Contract - Canon, Siemens, NIH
- Consultant Fee/Honoraria/Speaker's Bureau - Siemens; Boston Scientific Corporation; Biotronik; Acrostak; Medtronic; Fastwave
- Equity/Stock(s)/Options - Intravascular Imaging Incorporated, DurVena, Fastwave
- Royalty/Intellectual Property Rights - Massachusetts General Hospital (owns IP)